An update from INVO Bioscience ( (INVO) ) is now available.
INVO Bioscience and NAYA Biosciences have finalized their merger, with the combined company now operating as NAYA Biosciences. This union aims to leverage both companies’ strengths in fertility, oncology, and autoimmune disease sectors, offering innovative therapeutics and scalable business opportunities. The merger, which includes a strategic leadership team and conversion of preferred stocks, is expected to enhance investor value through an expanded portfolio and access to capital markets, despite ongoing compliance checks for Nasdaq listing requirements.
See more insights into INVO stock on TipRanks’ Stock Analysis page.
